Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?
2026-10-12 15:30
•Jeff Siegel •The Motley Fool
••• • Axe Cap view
Axsome’s Alzheimer’s Bet: High Risk, High Potential by 2030
Axsome Therapeutics’ Auvelity shows impressive early growth, aiming to transform treatment for brain disorders—but South African investors should weigh risks carefully.
Axsome’s Auvelity is carving out a promising niche beyond depression into Alzheimer's agitation, posting 51% revenue growth and a jump in senior patient starts. This demonstrates both strong demand and effective commercial execution. While this is an exciting biotech story globally, South African investors need to be cautious. The company’s long-term $8 billion sales target hinges on multiple regulatory approvals and sustained market uptake—both uncertain in a highly competitive field. For JSE watchers, this isn’t a direct play but a reminder of how innovation in pharma can take years to pay off. The rand’s strength against the dollar (USD/ZAR) could affect the local cost of investing in such offshore stocks. Axsome’s progress is worth watching but it’s not yet time to back it heavily. Execution risks and net losses mean patience is required, as early enthusiasm may not translate to reliable returns by 2030. this is just our opinion and not financial advice
Watch Axsome closely but avoid committing capital now. Better opportunities exist locally in healthcare-related stocks or stable rand-hedges. Consider USD/ZAR to gauge timing for any offshore biotech exposure.
- AXSM
- USD/ZAR
- Regulatory setbacks in drug approvals
- Sustained losses affecting company viability
5/10
Axsome Therapeutics' Auvelity drug is expanding beyond major depressive disorder into Alzheimer's agitation treatment, with Q2 sales reaching $180.3 million (up 51% YoY) and new patient starts among seniors jumping 126% post-launch. The company projects Auvelity could eventually generate $8 billion in annual peak sales, with additional commercial products and pipeline candidates potentially transforming Axsome into a major neuroscience pharmaceutical company by 2030.
Our take is based on reporting first published by The Motley Fool.